Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA267803
Max Phase: Preclinical
Molecular Formula: C10H16N5O4P
Molecular Weight: 301.24
Molecule Type: Small molecule
Associated Items:
ID: ALA267803
Max Phase: Preclinical
Molecular Formula: C10H16N5O4P
Molecular Weight: 301.24
Molecule Type: Small molecule
Associated Items:
Synonyms (1): 9-(5-Phosphonopentyl)Guanine
Synonyms from Alternative Forms(1):
Canonical SMILES: Nc1nc(O)c2ncn(CCCCCP(=O)(O)O)c2n1
Standard InChI: InChI=1S/C10H16N5O4P/c11-10-13-8-7(9(16)14-10)12-6-15(8)4-2-1-3-5-20(17,18)19/h6H,1-5H2,(H2,17,18,19)(H3,11,13,14,16)
Standard InChI Key: ZQMIYPAADORARG-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 301.24 | Molecular Weight (Monoisotopic): 301.0940 | AlogP: 0.46 | #Rotatable Bonds: 6 |
Polar Surface Area: 147.38 | Molecular Species: ACID | HBA: 7 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 1.87 | CX Basic pKa: 0.89 | CX LogP: -0.62 | CX LogD: -2.67 |
Aromatic Rings: 2 | Heavy Atoms: 20 | QED Weighted: 0.44 | Np Likeness Score: -0.63 |
1. Chern JW, Lee HY, Chen CS, Shewach DS, Daddona PE, Townsend LB.. (1993) Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase., 36 (8): [PMID:8478902] [10.1021/jm00060a010] |
2. Guida WC, Elliott RD, Thomas HJ, Secrist JA, Babu YS, Bugg CE, Erion MD, Ealick SE, Montgomery JA.. (1994) Structure-based design of inhibitors of purine nucleoside phosphorylase. 4. A study of phosphate mimics., 37 (8): [PMID:8164252] [10.1021/jm00034a008] |
3. Niwas S, Chand P, Pathak VP, Montgomery JA.. (1994) Structure-based design of inhibitors of purine nucleoside phosphorylase. 5. 9-Deazahypoxanthines., 37 (15): [PMID:8057293] [10.1021/jm00041a027] |
4. Česnek M, Hocková D, Holý A, Dračínský M, Baszczyňski O, Jersey Jd, Keough DT, Guddat LW.. (2012) Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases., 20 (2): [PMID:22178188] [10.1016/j.bmc.2011.11.034] |
Source(1):